Christoph Lindner

Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results

Oleg Gluz, Ulrike Nitz, Cornelia Liedtke et al. · JNCI Journal of the National Cancer Institute · 2017 · 132 citations · Full text

Medicine, Oncology, Pharmacology +17

Directed evolution of a recombinase that excises the provirus of most HIV-1 primary isolates with high specificity

Janet Karpinski, Ilona Hauber, Jan Chemnitz et al. · Nature Biotechnology · 2016 · 122 citations

Life Sciences, Genetics, Molecular Biology +15

De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial

Ulrike Nitz, Oleg Gluz, Monika Graeser et al. · The Lancet Oncology · 2022 · 83 citations

Medicine, Oncology, Pharmacology +17

Highly Significant Antiviral Activity of HIV-1 LTR-Specific Tre-Recombinase in Humanized Mice

Ilona Hauber, Helga Hofmann-Sieber, Jan Chemnitz et al. · PLoS Pathogens · 2013 · 61 citations · Full text

Life Sciences, Biotechnology, Molecular Biology +17

Carbonic anhydrase IX in tumor tissue and sera of patients with primary cervical cancer

Linn Woelber, Kerstin Kress, Jan Felix Kersten et al. · BMC Cancer · 2011 · 56 citations · Full text

Medicine, Oncology, Pathology +17